
What's next at Endpoints: a bigger, more ambitious newsroom
I’ve had a little over a month in the Executive Editor seat here at Endpoints News, and I want to take a moment to introduce myself to this great community of readers and talk about where we’re headed next.
For the last 20 years, I’ve been lucky to cover some of the biggest stories in healthcare. I had a front-row seat on Capitol Hill for the Affordable Care Act, wrote the first stories about our current drug price debate, and spent three years leading projects on the Covid-19 pandemic. During that time, we’ve witnessed amazing advances in the treatment of cancer, the manipulation of genetics and our understanding of human biology.
I came to Endpoints because those stories are only getting more complex, asking more from journalists, and hopefully offering more to readers.
The future of Endpoints, and much of news media, is in that complexity. “Trade journalism” for me has always been a misleading and under-ambitious description of what we do. I prefer the term “specialty journalism.” We’re a newsroom of experts focused on the biopharma industry – with the ability and ambition to compete with (and beat!) the biggest publications for scoops and smart analysis on our turf.
To that end, we’re hiring: Today we’ve posted six new jobs at Endpoints that will expand the size and ambition of our newsroom. You can find the listings here (along with descriptions of our great benefits and our work-from-home/anywhere policy). We’re adding to our editing ranks, and plan to hire writers and reporters to boost our science, venture capital and regulatory coverage.
We want people who are passionate about covering medical innovation and business, but also who see the journalism world the way we do: who believe that focus creates greatness, and that the next thriving newsrooms will be built by being smarter and breaking more news than anyone else on your beat.
The amazing writers and editors in this newsroom have made Endpoints into the first read for decision-makers in the biopharma world. As we expand, we’re going to deliver more scoops, more exclusive news, more smart perspective, and more ideas and reporting that you can’t get anywhere else.
As founding editor John Carroll mentioned in his note in November, this will also allow him to spend more time writing, interviewing and growing our business. You can expect to hear more from John over the coming months, as well as from the new voices that we’re excited to add.
Since I started exploring this job early in 2022, I’ve also been able to talk to many of you about what you read and how you read it. There are more changes ahead as we think about how to deliver news that makes the best use of our readers’ time, with the depth, analysis and seriousness they need.
As we make those changes, we want to hear from you. If you’ll be at JP Morgan next month, please stop in at our Endpoints event and say hello.
Thank you for reading, subscribing, and supporting us – I can’t wait to start showing you what this great newsroom has coming!